HomeCompareICPT vs CHD

ICPT vs CHD: Dividend Comparison 2026

ICPT yields 10.53% · CHD yields 1.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ICPT wins by $13.7K in total portfolio value
10 years
ICPT
ICPT
● Live price
10.53%
Share price
$19.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.1K
Annual income
$2,037.15
Full ICPT calculator →
CHD
CHD
● Live price
1.28%
Share price
$93.32
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,302.64
Full CHD calculator →

Portfolio growth — ICPT vs CHD

📍 ICPT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodICPTCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ICPT + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ICPT pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ICPT
Annual income on $10K today (after 15% tax)
$894.74/yr
After 10yr DRIP, annual income (after tax)
$1,731.58/yr
CHD
Annual income on $10K today (after 15% tax)
$108.62/yr
After 10yr DRIP, annual income (after tax)
$1,107.24/yr
At 15% tax rate, ICPT beats the other by $624.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ICPT + CHD for your $10,000?

ICPT: 50%CHD: 50%
100% CHD50/50100% ICPT
Portfolio after 10yr
$33.3K
Annual income
$1,669.89/yr
Blended yield
5.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

ICPT
Analyst Ratings
16
Buy
19
Hold
5
Sell
Consensus: Hold
Price Target
$22.11
+16.4% upside vs current
Range: $10.00 — $44.00
Altman Z
-5.0
Piotroski
3/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+5.4% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ICPT buys
0
CHD buys
11
PoliticianChamberTickerTypeAmountDate
Richard W. Allen🏢 House$CHD▼ Sell$15,001 - $50,0002025-10-10
Ro Khanna🏢 House$CHD▲ Buy$1,001 - $15,0002025-09-29
Lisa McClain🏢 House$CHD▼ Sell$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$CHD▲ Buy$1,001 - $15,0002025-08-04
Ro Khanna🏢 House$CHD▲ Buy$1,000 - $15,0002025-08-04
Lisa McClain🏢 House$CHD▼ Sell$1,001 - $15,0002025-06-24
Lisa McClain🏢 House$CHD▲ Buy$1,001 - $15,0002025-06-17
Jonathan Jackson🏢 House$CHD▼ Sell$15,001 - $50,0002025-05-14
Jonathan Jackson🏢 House$CHD▼ Sell$1,001 - $15,0002025-05-05
Jonathan Jackson🏢 House$CHD▲ Buy$1,001 - $15,0002025-04-23
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricICPTCHD
Forward yield10.53%1.28%
Annual dividend / share$2.00$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%23.1%
Portfolio after 10y$40.1K$26.4K
Annual income after 10y$2,037.15$1,302.64
Total dividends collected$15.4K$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$22.11$98.40

Year-by-year: ICPT vs CHD ($10,000, DRIP)

YearICPT PortfolioICPT Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$11,753$1,052.63$10,857$157.30+$896.00ICPT
2$13,732$1,156.19$11,814$196.49+$1.9KICPT
3$15,955$1,262.49$12,887$245.97+$3.1KICPT
4$18,443$1,370.97$14,097$308.68+$4.3KICPT
5$21,215$1,481.06$15,473$388.49+$5.7KICPT
6$24,292$1,592.22$17,046$490.55+$7.2KICPT
7$27,697$1,703.90$18,861$621.76+$8.8KICPT
8$31,451$1,815.59$20,973$791.47+$10.5KICPT
9$35,580$1,926.82$23,454$1,012.51+$12.1KICPT
10$40,107$2,037.15$26,398$1,302.64+$13.7KICPT

ICPT vs CHD: Complete Analysis 2026

ICPTStock

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Full ICPT Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this ICPT vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ICPT vs SCHDICPT vs JEPIICPT vs OICPT vs KOICPT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.